Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,785
  • Shares Outstanding, K 131,608
  • Annual Sales, $ 0 K
  • Annual Income, $ -101,700 K
  • EBIT $ -104 M
  • EBITDA $ -104 M
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.52

Options Overview Details

View History
  • Implied Volatility 189.55% (-79.43%)
  • Historical Volatility 67.64%
  • IV Percentile 11%
  • IV Rank 13.67%
  • IV High 1,013.27% on 06/11/25
  • IV Low 59.06% on 05/08/25
  • Expected Move (DTE 24) 1.0625 (60.71%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 528
  • Volume Avg (30-Day) 94
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 2,075
  • Open Int (30-Day) 2,486
  • Expected Range 0.6875 to 2.8125

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 2
  • High Estimate $-0.15
  • Low Estimate $-0.15
  • Prior Year $-0.58
  • Growth Rate Est. (year over year) +74.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +9.37%
on 04/10/26
2.2300 -21.52%
on 03/24/26
-0.4300 (-19.72%)
since 03/20/26
3-Month
1.3180 +32.78%
on 01/21/26
2.6600 -34.21%
on 02/19/26
+0.4300 (+32.58%)
since 01/20/26
52-Week
0.4040 +333.17%
on 06/27/25
2.6600 -34.21%
on 02/19/26
+1.2000 (+218.18%)
since 04/17/25

Most Recent Stories

More News
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 1.7500 (+4.79%)
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April ...

ALXO : 1.7500 (+4.79%)
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates...

ALXO : 1.7500 (+4.79%)
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 1.7500 (+4.79%)
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 1.7500 (+4.79%)
ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 1.7500 (+4.79%)
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ...

ALXO : 1.7500 (+4.79%)
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies...

ALXO : 1.7500 (+4.79%)
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...

ALXO : 1.7500 (+4.79%)
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

- Combination of evorpacept plus rituximab and lenalidomide (R 2 ) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an...

ALXO : 1.7500 (+4.79%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 1.9667
2nd Resistance Point 1.8833
1st Resistance Point 1.8167
Last Price 1.7500
1st Support Level 1.6667
2nd Support Level 1.5833
3rd Support Level 1.5167

See More

52-Week High 2.6600
Fibonacci 61.8% 1.7982
Last Price 1.7500
Fibonacci 50% 1.5320
Fibonacci 38.2% 1.2658
52-Week Low 0.4040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.